The use of immune checkpoint inhibitors (ICIs) has represented a major advance in cancer
treatment. By enhancing endogenous immune responses to destroy cancer cells, ICIs can …

Neurological, immune-related adverse events (n-irAE) due to immune checkpoint inhibitors
(ICI) represent a growing clinical problem in neuro-oncology practice. Although rare, the …

Immunotherapy with immune checkpoint inhibitors (ICIs) have been reported to induce de
novo or exacerbate pre-existing Myasthenia Gravis (MG). We present a single center case …

Recent advances in cancer immunotherapy have completely revolutionized cancer
treatment strategies. Nonetheless, the increasing incidence of immune-related adverse …

Anti CTLA-4 therapy is aimed at blocking the Cytotoxic T-lymphocyte antigen-4 (CTLA-4), a
key cancer immunity cycle checkpoint. The mechanism of action of CTLA-4 may be …

Immune checkpoint inhibitors (ICI) have improved metastatic melanoma outcomes; however,
toxicities, such as hepatitis, can be dose-limiting or even fatal. 1 Systemic glucocorticoids …

The increasing use of immune checkpoint inhibitors (ICI) in cancer therapy has brought
attention to their associated neurotoxicities, termed neurological immune-related adverse …

Aim To detect immune‐related adverse events (irAEs) early and treat them appropriately,
our institute established an irAE‐focused multidisciplinary toxicity team in cooperation with …

Simple Summary Immune-related adverse events (irAEs) are becoming an increasingly
prevalent and well-studied phenomenon. Little is known about how clinical practice has …

Background Although immune checkpoint inhibitors (ICIs) show a more favorable toxicity
profile than classical cytotoxic drugs, their mechanism of action is responsible for peculiar …